Majority of top-selling Medicare drugs offer little added benefit to alternatives, researchers find
When Medicare begins negotiating prices for some of the most expensive drugs in 2026, Harvard researchers are calling on CMS to ensure they are not …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
